nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—CYP1A1—Riluzole—amyotrophic lateral sclerosis	0.301	0.691	CbGbCtD
Thalidomide—PTGS2—amyotrophic lateral sclerosis	0.25	1	CbGaD
Thalidomide—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.134	0.309	CbGbCtD
Thalidomide—Peritonitis—Riluzole—amyotrophic lateral sclerosis	0.00439	0.0236	CcSEcCtD
Thalidomide—Circumoral paresthesia—Riluzole—amyotrophic lateral sclerosis	0.0034	0.0183	CcSEcCtD
Thalidomide—Hypochromic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00286	0.0154	CcSEcCtD
Thalidomide—Dementia—Riluzole—amyotrophic lateral sclerosis	0.0027	0.0146	CcSEcCtD
Thalidomide—Fungal skin infection—Riluzole—amyotrophic lateral sclerosis	0.00265	0.0143	CcSEcCtD
Thalidomide—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.00256	0.0138	CcSEcCtD
Thalidomide—Paraesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.00236	0.0127	CcSEcCtD
Thalidomide—Hernia—Riluzole—amyotrophic lateral sclerosis	0.00236	0.0127	CcSEcCtD
Thalidomide—FGFR2—hindbrain—amyotrophic lateral sclerosis	0.00229	0.0895	CbGeAlD
Thalidomide—Cerebral ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00229	0.0124	CcSEcCtD
Thalidomide—Tongue discolouration—Riluzole—amyotrophic lateral sclerosis	0.00229	0.0124	CcSEcCtD
Thalidomide—Peripheral vascular disorder—Riluzole—amyotrophic lateral sclerosis	0.00226	0.0122	CcSEcCtD
Thalidomide—White blood cell count decreased—Riluzole—amyotrophic lateral sclerosis	0.00223	0.012	CcSEcCtD
Thalidomide—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00217	0.0117	CcSEcCtD
Thalidomide—Hostility—Riluzole—amyotrophic lateral sclerosis	0.002	0.0108	CcSEcCtD
Thalidomide—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.00195	0.0105	CcSEcCtD
Thalidomide—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00191	0.0103	CcSEcCtD
Thalidomide—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.00186	0.01	CcSEcCtD
Thalidomide—Enlargement abdomen—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00993	CcSEcCtD
Thalidomide—Psoriasis—Riluzole—amyotrophic lateral sclerosis	0.00176	0.0095	CcSEcCtD
Thalidomide—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.00176	0.0095	CcSEcCtD
Thalidomide—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00174	0.0094	CcSEcCtD
Thalidomide—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00173	0.00931	CcSEcCtD
Thalidomide—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00921	CcSEcCtD
Thalidomide—Seborrhoeic dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00876	CcSEcCtD
Thalidomide—Intestinal obstruction—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00876	CcSEcCtD
Thalidomide—CRBN—embryo—amyotrophic lateral sclerosis	0.0016	0.0625	CbGeAlD
Thalidomide—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00159	0.0086	CcSEcCtD
Thalidomide—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00844	CcSEcCtD
Thalidomide—Cyanosis—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00844	CcSEcCtD
Thalidomide—Lung disorder—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00844	CcSEcCtD
Thalidomide—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00844	CcSEcCtD
Thalidomide—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00836	CcSEcCtD
Thalidomide—PTGS2—hindlimb—amyotrophic lateral sclerosis	0.00153	0.0597	CbGeAlD
Thalidomide—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.00148	0.008	CcSEcCtD
Thalidomide—Stupor—Riluzole—amyotrophic lateral sclerosis	0.00148	0.008	CcSEcCtD
Thalidomide—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00145	0.0078	CcSEcCtD
Thalidomide—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00774	CcSEcCtD
Thalidomide—FGFR2—embryo—amyotrophic lateral sclerosis	0.00143	0.056	CbGeAlD
Thalidomide—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00767	CcSEcCtD
Thalidomide—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00743	CcSEcCtD
Thalidomide—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00135	0.00726	CcSEcCtD
Thalidomide—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00721	CcSEcCtD
Thalidomide—FGFR2—brainstem—amyotrophic lateral sclerosis	0.00131	0.0513	CbGeAlD
Thalidomide—PTGS2—appendage—amyotrophic lateral sclerosis	0.00131	0.0512	CbGeAlD
Thalidomide—Apnoea—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00705	CcSEcCtD
Thalidomide—Lenalidomide—PTGS2—amyotrophic lateral sclerosis	0.0013	0.518	CrCbGaD
Thalidomide—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00126	0.0068	CcSEcCtD
Thalidomide—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00675	CcSEcCtD
Thalidomide—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00666	CcSEcCtD
Thalidomide—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00661	CcSEcCtD
Thalidomide—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00657	CcSEcCtD
Thalidomide—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00657	CcSEcCtD
Thalidomide—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00653	CcSEcCtD
Thalidomide—Pomalidomide—PTGS2—amyotrophic lateral sclerosis	0.0012	0.482	CrCbGaD
Thalidomide—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00636	CcSEcCtD
Thalidomide—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00632	CcSEcCtD
Thalidomide—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00612	CcSEcCtD
Thalidomide—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00608	CcSEcCtD
Thalidomide—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00605	CcSEcCtD
Thalidomide—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00597	CcSEcCtD
Thalidomide—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00597	CcSEcCtD
Thalidomide—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00597	CcSEcCtD
Thalidomide—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00577	CcSEcCtD
Thalidomide—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00106	0.0057	CcSEcCtD
Thalidomide—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00561	CcSEcCtD
Thalidomide—CRBN—medulla oblongata—amyotrophic lateral sclerosis	0.00102	0.0399	CbGeAlD
Thalidomide—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00549	CcSEcCtD
Thalidomide—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.000986	0.00532	CcSEcCtD
Thalidomide—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.000971	0.00524	CcSEcCtD
Thalidomide—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.000961	0.00518	CcSEcCtD
Thalidomide—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.000961	0.00518	CcSEcCtD
Thalidomide—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.000952	0.00513	CcSEcCtD
Thalidomide—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.000943	0.00508	CcSEcCtD
Thalidomide—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.000925	0.00499	CcSEcCtD
Thalidomide—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.000925	0.00499	CcSEcCtD
Thalidomide—NFKB1—nervous system—amyotrophic lateral sclerosis	0.000917	0.0358	CbGeAlD
Thalidomide—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.000916	0.00494	CcSEcCtD
Thalidomide—CRBN—spinal cord—amyotrophic lateral sclerosis	0.000912	0.0356	CbGeAlD
Thalidomide—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.000899	0.00485	CcSEcCtD
Thalidomide—Deafness—Riluzole—amyotrophic lateral sclerosis	0.000899	0.00485	CcSEcCtD
Thalidomide—Eczema—Riluzole—amyotrophic lateral sclerosis	0.000895	0.00483	CcSEcCtD
Thalidomide—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.000887	0.00478	CcSEcCtD
Thalidomide—NFKB1—central nervous system—amyotrophic lateral sclerosis	0.000883	0.0345	CbGeAlD
Thalidomide—Injury—Riluzole—amyotrophic lateral sclerosis	0.000875	0.00472	CcSEcCtD
Thalidomide—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.000867	0.00468	CcSEcCtD
Thalidomide—NFKB1—cerebellum—amyotrophic lateral sclerosis	0.000863	0.0337	CbGeAlD
Thalidomide—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.000856	0.00462	CcSEcCtD
Thalidomide—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.000856	0.00462	CcSEcCtD
Thalidomide—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.000852	0.0046	CcSEcCtD
Thalidomide—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.000849	0.00458	CcSEcCtD
Thalidomide—Purpura—Riluzole—amyotrophic lateral sclerosis	0.000834	0.0045	CcSEcCtD
Thalidomide—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.000828	0.00446	CcSEcCtD
Thalidomide—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.000824	0.00444	CcSEcCtD
Thalidomide—FGFR2—spinal cord—amyotrophic lateral sclerosis	0.000817	0.0319	CbGeAlD
Thalidomide—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.000807	0.00435	CcSEcCtD
Thalidomide—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000804	0.00434	CcSEcCtD
Thalidomide—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.000804	0.00434	CcSEcCtD
Thalidomide—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.000804	0.00434	CcSEcCtD
Thalidomide—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.000798	0.0043	CcSEcCtD
Thalidomide—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.000792	0.00427	CcSEcCtD
Thalidomide—Migraine—Riluzole—amyotrophic lateral sclerosis	0.000792	0.00427	CcSEcCtD
Thalidomide—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.000785	0.00424	CcSEcCtD
Thalidomide—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.000776	0.00419	CcSEcCtD
Thalidomide—CRBN—nervous system—amyotrophic lateral sclerosis	0.000768	0.03	CbGeAlD
Thalidomide—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.000765	0.00412	CcSEcCtD
Thalidomide—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.000762	0.00411	CcSEcCtD
Thalidomide—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.000756	0.00408	CcSEcCtD
Thalidomide—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.000748	0.00403	CcSEcCtD
Thalidomide—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.000743	0.004	CcSEcCtD
Thalidomide—CRBN—central nervous system—amyotrophic lateral sclerosis	0.00074	0.0289	CbGeAlD
Thalidomide—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.000735	0.00396	CcSEcCtD
Thalidomide—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.000732	0.00395	CcSEcCtD
Thalidomide—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.000727	0.00392	CcSEcCtD
Thalidomide—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.000724	0.0039	CcSEcCtD
Thalidomide—CRBN—cerebellum—amyotrophic lateral sclerosis	0.000723	0.0282	CbGeAlD
Thalidomide—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.000709	0.00382	CcSEcCtD
Thalidomide—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.000709	0.00382	CcSEcCtD
Thalidomide—NFKB1—brain—amyotrophic lateral sclerosis	0.000701	0.0274	CbGeAlD
Thalidomide—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.0007	0.00377	CcSEcCtD
Thalidomide—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.000695	0.00375	CcSEcCtD
Thalidomide—Influenza—Riluzole—amyotrophic lateral sclerosis	0.000695	0.00375	CcSEcCtD
Thalidomide—FGFR2—nervous system—amyotrophic lateral sclerosis	0.000689	0.0269	CbGeAlD
Thalidomide—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.000682	0.00367	CcSEcCtD
Thalidomide—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.000677	0.00365	CcSEcCtD
Thalidomide—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.000668	0.0036	CcSEcCtD
Thalidomide—FGFR2—central nervous system—amyotrophic lateral sclerosis	0.000663	0.0259	CbGeAlD
Thalidomide—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00066	0.00356	CcSEcCtD
Thalidomide—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00065	0.0035	CcSEcCtD
Thalidomide—FGFR2—cerebellum—amyotrophic lateral sclerosis	0.000648	0.0253	CbGeAlD
Thalidomide—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.000642	0.00346	CcSEcCtD
Thalidomide—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00064	0.00345	CcSEcCtD
Thalidomide—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.000634	0.00342	CcSEcCtD
Thalidomide—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.000633	0.00341	CcSEcCtD
Thalidomide—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.000629	0.00339	CcSEcCtD
Thalidomide—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.000623	0.00336	CcSEcCtD
Thalidomide—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00062	0.00334	CcSEcCtD
Thalidomide—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00062	0.00334	CcSEcCtD
Thalidomide—Depression—Riluzole—amyotrophic lateral sclerosis	0.000618	0.00333	CcSEcCtD
Thalidomide—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.000611	0.00329	CcSEcCtD
Thalidomide—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.000608	0.00328	CcSEcCtD
Thalidomide—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.000608	0.00328	CcSEcCtD
Thalidomide—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.000604	0.00326	CcSEcCtD
Thalidomide—Sweating—Riluzole—amyotrophic lateral sclerosis	0.000594	0.0032	CcSEcCtD
Thalidomide—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.000591	0.00319	CcSEcCtD
Thalidomide—CRBN—brain—amyotrophic lateral sclerosis	0.000587	0.0229	CbGeAlD
Thalidomide—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000585	0.00315	CcSEcCtD
Thalidomide—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.000581	0.00314	CcSEcCtD
Thalidomide—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.000578	0.00312	CcSEcCtD
Thalidomide—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.000566	0.00305	CcSEcCtD
Thalidomide—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.000558	0.00301	CcSEcCtD
Thalidomide—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000556	0.003	CcSEcCtD
Thalidomide—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.000554	0.00298	CcSEcCtD
Thalidomide—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.000552	0.00298	CcSEcCtD
Thalidomide—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000549	0.00296	CcSEcCtD
Thalidomide—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.000548	0.00296	CcSEcCtD
Thalidomide—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000545	0.00294	CcSEcCtD
Thalidomide—FGFR2—brain—amyotrophic lateral sclerosis	0.000526	0.0205	CbGeAlD
Thalidomide—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000526	0.00284	CcSEcCtD
Thalidomide—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00052	0.0028	CcSEcCtD
Thalidomide—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000516	0.00278	CcSEcCtD
Thalidomide—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000505	0.00272	CcSEcCtD
Thalidomide—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000503	0.00271	CcSEcCtD
Thalidomide—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000501	0.0027	CcSEcCtD
Thalidomide—Chills—Riluzole—amyotrophic lateral sclerosis	0.000499	0.00269	CcSEcCtD
Thalidomide—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000497	0.00268	CcSEcCtD
Thalidomide—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000492	0.00265	CcSEcCtD
Thalidomide—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000487	0.00263	CcSEcCtD
Thalidomide—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000484	0.00261	CcSEcCtD
Thalidomide—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000477	0.00257	CcSEcCtD
Thalidomide—Tension—Riluzole—amyotrophic lateral sclerosis	0.000475	0.00256	CcSEcCtD
Thalidomide—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000474	0.00256	CcSEcCtD
Thalidomide—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00047	0.00254	CcSEcCtD
Thalidomide—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000468	0.00253	CcSEcCtD
Thalidomide—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000466	0.00251	CcSEcCtD
Thalidomide—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000454	0.00245	CcSEcCtD
Thalidomide—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000449	0.00242	CcSEcCtD
Thalidomide—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000448	0.00241	CcSEcCtD
Thalidomide—Agitation—Riluzole—amyotrophic lateral sclerosis	0.000445	0.0024	CcSEcCtD
Thalidomide—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000443	0.00239	CcSEcCtD
Thalidomide—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000437	0.00235	CcSEcCtD
Thalidomide—PTGS2—embryo—amyotrophic lateral sclerosis	0.000436	0.017	CbGeAlD
Thalidomide—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000435	0.00235	CcSEcCtD
Thalidomide—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000434	0.00234	CcSEcCtD
Thalidomide—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000434	0.00234	CcSEcCtD
Thalidomide—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000428	0.00231	CcSEcCtD
Thalidomide—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000426	0.0023	CcSEcCtD
Thalidomide—Cough—Riluzole—amyotrophic lateral sclerosis	0.000423	0.00228	CcSEcCtD
Thalidomide—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00042	0.00226	CcSEcCtD
Thalidomide—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000418	0.00225	CcSEcCtD
Thalidomide—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000412	0.00222	CcSEcCtD
Thalidomide—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000412	0.00222	CcSEcCtD
Thalidomide—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000412	0.00222	CcSEcCtD
Thalidomide—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000411	0.00222	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00041	0.00221	CcSEcCtD
Thalidomide—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000407	0.0022	CcSEcCtD
Thalidomide—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000403	0.00217	CcSEcCtD
Thalidomide—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000399	0.00215	CcSEcCtD
Thalidomide—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000395	0.00213	CcSEcCtD
Thalidomide—Infection—Riluzole—amyotrophic lateral sclerosis	0.000393	0.00212	CcSEcCtD
Thalidomide—Shock—Riluzole—amyotrophic lateral sclerosis	0.000389	0.0021	CcSEcCtD
Thalidomide—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000388	0.00209	CcSEcCtD
Thalidomide—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000387	0.00209	CcSEcCtD
Thalidomide—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000386	0.00208	CcSEcCtD
Thalidomide—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000384	0.00207	CcSEcCtD
Thalidomide—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000382	0.00206	CcSEcCtD
Thalidomide—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000377	0.00203	CcSEcCtD
Thalidomide—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000369	0.00199	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00036	0.00194	CcSEcCtD
Thalidomide—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000358	0.00193	CcSEcCtD
Thalidomide—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000355	0.00191	CcSEcCtD
Thalidomide—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000352	0.0019	CcSEcCtD
Thalidomide—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000351	0.00189	CcSEcCtD
Thalidomide—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000348	0.00188	CcSEcCtD
Thalidomide—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000344	0.00185	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000341	0.00184	CcSEcCtD
Thalidomide—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000341	0.00184	CcSEcCtD
Thalidomide—Pain—Riluzole—amyotrophic lateral sclerosis	0.000338	0.00182	CcSEcCtD
Thalidomide—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000338	0.00182	CcSEcCtD
Thalidomide—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000326	0.00176	CcSEcCtD
Thalidomide—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000323	0.00174	CcSEcCtD
Thalidomide—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000314	0.00169	CcSEcCtD
Thalidomide—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000312	0.00168	CcSEcCtD
Thalidomide—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000312	0.00168	CcSEcCtD
Thalidomide—CYP2E1—medulla oblongata—amyotrophic lateral sclerosis	0.000302	0.0118	CbGeAlD
Thalidomide—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000291	0.00157	CcSEcCtD
Thalidomide—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000284	0.00153	CcSEcCtD
Thalidomide—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00028	0.00151	CcSEcCtD
Thalidomide—PTGS2—medulla oblongata—amyotrophic lateral sclerosis	0.000278	0.0109	CbGeAlD
Thalidomide—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00027	0.00146	CcSEcCtD
Thalidomide—CYP2E1—spinal cord—amyotrophic lateral sclerosis	0.00027	0.0105	CbGeAlD
Thalidomide—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000261	0.00141	CcSEcCtD
Thalidomide—PTGS1—spinal cord—amyotrophic lateral sclerosis	0.00026	0.0101	CbGeAlD
Thalidomide—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000251	0.00136	CcSEcCtD
Thalidomide—Rash—Riluzole—amyotrophic lateral sclerosis	0.000249	0.00134	CcSEcCtD
Thalidomide—CYP1A1—nervous system—amyotrophic lateral sclerosis	0.000249	0.00973	CbGeAlD
Thalidomide—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000249	0.00134	CcSEcCtD
Thalidomide—PTGS2—spinal cord—amyotrophic lateral sclerosis	0.000248	0.0097	CbGeAlD
Thalidomide—Headache—Riluzole—amyotrophic lateral sclerosis	0.000248	0.00134	CcSEcCtD
Thalidomide—CYP1A1—central nervous system—amyotrophic lateral sclerosis	0.00024	0.00937	CbGeAlD
Thalidomide—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000235	0.00127	CcSEcCtD
Thalidomide—CYP2E1—nervous system—amyotrophic lateral sclerosis	0.000227	0.00887	CbGeAlD
Thalidomide—PTGS1—nervous system—amyotrophic lateral sclerosis	0.000219	0.00855	CbGeAlD
Thalidomide—CYP2E1—central nervous system—amyotrophic lateral sclerosis	0.000219	0.00854	CbGeAlD
Thalidomide—CYP2E1—cerebellum—amyotrophic lateral sclerosis	0.000214	0.00835	CbGeAlD
Thalidomide—PTGS1—central nervous system—amyotrophic lateral sclerosis	0.000211	0.00823	CbGeAlD
Thalidomide—PTGS2—nervous system—amyotrophic lateral sclerosis	0.000209	0.00817	CbGeAlD
Thalidomide—PTGS2—central nervous system—amyotrophic lateral sclerosis	0.000201	0.00787	CbGeAlD
Thalidomide—PTGS2—cerebellum—amyotrophic lateral sclerosis	0.000197	0.00769	CbGeAlD
Thalidomide—CYP1A1—brain—amyotrophic lateral sclerosis	0.00019	0.00744	CbGeAlD
Thalidomide—CYP2E1—brain—amyotrophic lateral sclerosis	0.000174	0.00678	CbGeAlD
Thalidomide—PTGS1—brain—amyotrophic lateral sclerosis	0.000167	0.00653	CbGeAlD
Thalidomide—PTGS2—brain—amyotrophic lateral sclerosis	0.00016	0.00624	CbGeAlD
Thalidomide—FGFR2—Immune System—DCTN1—amyotrophic lateral sclerosis	5.52e-05	0.000547	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	5.52e-05	0.000547	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.5e-05	0.000545	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	5.48e-05	0.000543	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—amyotrophic lateral sclerosis	5.48e-05	0.000543	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	5.48e-05	0.000543	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—VAPA—amyotrophic lateral sclerosis	5.47e-05	0.000542	CbGpPWpGaD
Thalidomide—CYP1A1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.42e-05	0.000537	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CASP9—amyotrophic lateral sclerosis	5.41e-05	0.000536	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—CASP3—amyotrophic lateral sclerosis	5.24e-05	0.000519	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	5.24e-05	0.000519	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	5.22e-05	0.000517	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	5.21e-05	0.000516	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	5.2e-05	0.000515	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	5.18e-05	0.000514	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	5.13e-05	0.000508	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.09e-05	0.000504	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	4.93e-05	0.000489	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	4.91e-05	0.000486	CbGpPWpGaD
Thalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	4.88e-05	0.000484	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	4.88e-05	0.000484	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	4.82e-05	0.000478	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—FIG4—amyotrophic lateral sclerosis	4.78e-05	0.000474	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	4.77e-05	0.000473	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TPK1—amyotrophic lateral sclerosis	4.75e-05	0.00047	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—VAPB—amyotrophic lateral sclerosis	4.75e-05	0.00047	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	4.69e-05	0.000464	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	4.63e-05	0.000459	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	4.62e-05	0.000457	CbGpPWpGaD
Thalidomide—PTGS2—Disease—VTA1—amyotrophic lateral sclerosis	4.53e-05	0.000449	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.5e-05	0.000446	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	4.5e-05	0.000446	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—VAPB—amyotrophic lateral sclerosis	4.47e-05	0.000443	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TPK1—amyotrophic lateral sclerosis	4.47e-05	0.000443	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—VAPB—amyotrophic lateral sclerosis	4.46e-05	0.000442	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TPK1—amyotrophic lateral sclerosis	4.46e-05	0.000442	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	4.45e-05	0.000441	CbGpPWpGaD
Thalidomide—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.44e-05	0.00044	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	4.43e-05	0.000439	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.43e-05	0.000439	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	4.42e-05	0.000438	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	4.41e-05	0.000437	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	4.38e-05	0.000434	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—VAPA—amyotrophic lateral sclerosis	4.34e-05	0.00043	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	4.34e-05	0.00043	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—DAO—amyotrophic lateral sclerosis	4.32e-05	0.000428	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	4.24e-05	0.00042	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TPK1—amyotrophic lateral sclerosis	4.21e-05	0.000418	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—VAPB—amyotrophic lateral sclerosis	4.21e-05	0.000418	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	4.21e-05	0.000417	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	4.18e-05	0.000414	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	4.18e-05	0.000414	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	4.13e-05	0.000409	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	4.12e-05	0.000408	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	4.11e-05	0.000408	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	4.11e-05	0.000407	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.1e-05	0.000407	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—VAPA—amyotrophic lateral sclerosis	4.09e-05	0.000405	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	4.08e-05	0.000404	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—C3—amyotrophic lateral sclerosis	4.06e-05	0.000402	CbGpPWpGaD
Thalidomide—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.05e-05	0.000401	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.04e-05	0.0004	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	4.03e-05	0.000399	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CST3—amyotrophic lateral sclerosis	4e-05	0.000396	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	3.99e-05	0.000396	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	3.99e-05	0.000395	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.93e-05	0.000389	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	3.9e-05	0.000387	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—C3—amyotrophic lateral sclerosis	3.89e-05	0.000386	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	3.87e-05	0.000383	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—VAPA—amyotrophic lateral sclerosis	3.85e-05	0.000382	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—C3—amyotrophic lateral sclerosis	3.85e-05	0.000381	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—VEGFA—amyotrophic lateral sclerosis	3.81e-05	0.000377	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—amyotrophic lateral sclerosis	3.81e-05	0.000377	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	3.81e-05	0.000377	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.8e-05	0.000377	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—FIG4—amyotrophic lateral sclerosis	3.8e-05	0.000376	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.79e-05	0.000376	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	3.78e-05	0.000375	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	3.76e-05	0.000373	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.73e-05	0.000369	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—SQSTM1—amyotrophic lateral sclerosis	3.72e-05	0.000368	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—C3—amyotrophic lateral sclerosis	3.7e-05	0.000366	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.58e-05	0.000355	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—FIG4—amyotrophic lateral sclerosis	3.57e-05	0.000354	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	3.57e-05	0.000353	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	3.56e-05	0.000353	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	3.54e-05	0.000351	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—SQSTM1—amyotrophic lateral sclerosis	3.53e-05	0.00035	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	3.51e-05	0.000347	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	3.5e-05	0.000347	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ATF1—amyotrophic lateral sclerosis	3.49e-05	0.000345	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	3.46e-05	0.000343	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	3.45e-05	0.000342	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	3.45e-05	0.000342	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CHMP2B—amyotrophic lateral sclerosis	3.43e-05	0.00034	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—DAO—amyotrophic lateral sclerosis	3.43e-05	0.00034	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—FIG4—amyotrophic lateral sclerosis	3.37e-05	0.000334	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—amyotrophic lateral sclerosis	3.36e-05	0.000333	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	3.36e-05	0.000333	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CASP9—amyotrophic lateral sclerosis	3.32e-05	0.000329	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	3.32e-05	0.000329	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ATF1—amyotrophic lateral sclerosis	3.31e-05	0.000328	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	3.31e-05	0.000328	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.28e-05	0.000325	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—DAO—amyotrophic lateral sclerosis	3.23e-05	0.00032	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	3.22e-05	0.000319	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.22e-05	0.000319	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	3.15e-05	0.000312	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CASP9—amyotrophic lateral sclerosis	3.15e-05	0.000312	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	3.15e-05	0.000312	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	3.14e-05	0.000312	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	3.14e-05	0.000312	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PLB1—amyotrophic lateral sclerosis	3.11e-05	0.000308	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—DAO—amyotrophic lateral sclerosis	3.05e-05	0.000302	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSR—amyotrophic lateral sclerosis	3.02e-05	0.0003	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.93e-05	0.000291	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.93e-05	0.00029	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CASP9—amyotrophic lateral sclerosis	2.91e-05	0.000288	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—amyotrophic lateral sclerosis	2.88e-05	0.000285	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	2.88e-05	0.000285	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ERBB4—amyotrophic lateral sclerosis	2.84e-05	0.000282	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.84e-05	0.000281	CbGpPWpGaD
Thalidomide—PTGS2—Disease—VCP—amyotrophic lateral sclerosis	2.77e-05	0.000274	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	2.76e-05	0.000273	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.75e-05	0.000273	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	2.74e-05	0.000271	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERBB4—amyotrophic lateral sclerosis	2.7e-05	0.000267	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	2.69e-05	0.000266	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	2.69e-05	0.000266	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.67e-05	0.000265	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD40LG—amyotrophic lateral sclerosis	2.67e-05	0.000265	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PLB1—amyotrophic lateral sclerosis	2.6e-05	0.000258	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	2.58e-05	0.000256	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	2.57e-05	0.000255	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD40LG—amyotrophic lateral sclerosis	2.54e-05	0.000251	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	2.51e-05	0.000249	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.51e-05	0.000248	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	2.49e-05	0.000247	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERBB4—amyotrophic lateral sclerosis	2.49e-05	0.000247	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.48e-05	0.000246	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	2.46e-05	0.000243	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.45e-05	0.000243	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	2.44e-05	0.000242	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.4e-05	0.000238	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSR—amyotrophic lateral sclerosis	2.4e-05	0.000238	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—C3—amyotrophic lateral sclerosis	2.36e-05	0.000234	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.33e-05	0.00023	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.31e-05	0.000229	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.31e-05	0.000229	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.28e-05	0.000226	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.28e-05	0.000226	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	2.27e-05	0.000225	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.27e-05	0.000225	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSR—amyotrophic lateral sclerosis	2.26e-05	0.000224	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	2.26e-05	0.000223	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.25e-05	0.000223	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—C3—amyotrophic lateral sclerosis	2.24e-05	0.000222	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.19e-05	0.000217	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.15e-05	0.000213	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.15e-05	0.000213	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.14e-05	0.000212	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSR—amyotrophic lateral sclerosis	2.13e-05	0.000211	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.04e-05	0.000202	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CST3—amyotrophic lateral sclerosis	1.99e-05	0.000197	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.97e-05	0.000195	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.96e-05	0.000194	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	1.94e-05	0.000192	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.94e-05	0.000192	CbGpPWpGaD
Thalidomide—FGFR2—Disease—APOE—amyotrophic lateral sclerosis	1.93e-05	0.000191	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	1.89e-05	0.000187	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.86e-05	0.000184	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	1.85e-05	0.000184	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.84e-05	0.000182	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.8e-05	0.000178	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.76e-05	0.000174	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.76e-05	0.000174	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.75e-05	0.000173	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.74e-05	0.000173	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	1.74e-05	0.000173	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.73e-05	0.000171	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	1.72e-05	0.000171	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.64e-05	0.000162	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.6e-05	0.000158	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	1.59e-05	0.000158	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.59e-05	0.000157	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.55e-05	0.000154	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.53e-05	0.000151	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.47e-05	0.000146	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.45e-05	0.000144	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.45e-05	0.000143	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CASP9—amyotrophic lateral sclerosis	1.44e-05	0.000143	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	1.43e-05	0.000142	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.42e-05	0.000141	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.36e-05	0.000135	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.35e-05	0.000134	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.33e-05	0.000132	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—amyotrophic lateral sclerosis	1.32e-05	0.000131	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.31e-05	0.000129	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	1.31e-05	0.000129	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.24e-05	0.000123	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB4—amyotrophic lateral sclerosis	1.24e-05	0.000123	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.23e-05	0.000122	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.19e-05	0.000118	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.17e-05	0.000116	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.12e-05	0.000111	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.11e-05	0.00011	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.09e-05	0.000108	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.06e-05	0.000105	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.02e-05	0.000101	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—amyotrophic lateral sclerosis	1.01e-05	0.0001	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.98e-06	9.88e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.95e-06	9.86e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.74e-06	9.65e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—amyotrophic lateral sclerosis	9.57e-06	9.48e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.4e-06	9.32e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.17e-06	9.08e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.15e-06	9.06e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	9.04e-06	8.96e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.95e-06	8.87e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.64e-06	8.56e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.58e-06	8.5e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.55e-06	8.47e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.16e-06	8.09e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	8.11e-06	8.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—amyotrophic lateral sclerosis	8.01e-06	7.94e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.7e-06	7.62e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.67e-06	7.6e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—amyotrophic lateral sclerosis	7.54e-06	7.47e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	7.53e-06	7.46e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	7.28e-06	7.21e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—amyotrophic lateral sclerosis	7.11e-06	7.04e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.07e-06	7.01e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.02e-06	6.95e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	6.98e-06	6.91e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.92e-06	6.85e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.45e-06	6.39e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	6e-06	5.94e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	5.82e-06	5.76e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.8e-06	5.74e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.51e-06	5.46e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.5e-06	5.45e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	5.31e-06	5.26e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.17e-06	5.12e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.16e-06	5.11e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.87e-06	4.83e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	4.53e-06	4.49e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.99e-06	3.95e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.64e-06	3.6e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.11e-06	3.08e-05	CbGpPWpGaD
